Allergan Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 220 Posts
1 2 3 ... 14
Allergan Reports Q2 Earnings Beat, Reaffirms Guidance
Article By: Benzinga Tuesday, August 6, 2019 9:06 AM EDT
Allergan reported second-quarter earnings of $4.38 per share, which beat the analyst consensus estimate of $4.34 by 0.92%.
In this article: AGN
Read
Long Thesis For Allergan
Article By: ValueWalk Sunday, July 14, 2019 2:43 PM EDT
Quintessential Capital's Gabriel Grego recently shared a rare long call for Allergan. This is interesting not only because AGN was once a hot short position due to Bill Ackman, but also because Grego is known for his shorts.
In this article: AGN
Read
3 Dividend Stocks Retirees Must Have In Their Portfolio
Article By: SureDividend Sunday, July 7, 2019 2:18 AM EDT
Investing in strong dividend growers will help you live a stress-free retirement. Even if we are currently trading at an all-time high, Mr. Market offers us a few great opportunities. Here are my favorites right now.
In this article: ABT, AGN, ENB, LAZ, ABBV
Read
E American Depositary Receipts
Article By: Vivian Lewis Thursday, June 27, 2019 12:01 AM EDT
The medical devices firm Smith & Nephew pondered creating an ADR listing in order to pay their new CEO Narnal Nawana a higher salary than would have been tolerated by UK shareholders. And more on global stocks.
In this article: ANFGF, CRH, GNCGY, MELI, NPSNY, TCEHY, AAIGF, TEVA, AGN, ZYME, VOD, CGEN, GNFTF, BHC, BT, AQN, DCMYY, AZRE, FBASF, GLD
Read
Abbvie To Buy Allergan For $60 Billion In Latest Pharma Megadeal
Article By: Tyler Durden Tuesday, June 25, 2019 7:14 AM EDT
Abbvie will pay most of the price, represents a 45% premium over Allergan’s closing share price Monday of $129.57, in cash.
In this article: ABBV, AGN
Read
Allergan Recent Selloff 'Very Much Overdone,' Says JPMorgan
Article By: The Fly Wednesday, June 19, 2019 9:07 AM EDT
With Allergan shares down 14% over the last 30 days, JPMorgan analyst Chris Schott calls the recent selloff "very much overdone."
In this article: AGN
Read
Undervalued Growth And Dividend Growth In Health Technology
Article By: Chuck Carnevale Wednesday, March 20, 2019 11:13 AM EDT
Although many Health Technology Sector companies have significantly outperformed the market on a long-term basis, they have significantly underperformed the market since the beginning of 2015.
In this article: ABBV, AGN, AMGN, BMY, BIIB, CELG, GILD, MYL, PFE, PRGO
Read
Wall Street's Top Stories For Tuesday, Jan. 29th
Article By: The Fly Tuesday, January 29, 2019 4:08 PM EDT
Stocks have mixed day as investors await Apple earnings.
In this article: AGN, EAT, GME, MMM, PCG, PFE, VZ, AAPL, SANM, WWD, FMCC, FNMA, SQ, OCX
Read
How Trump's Policies Moved Stocks - Dec. 23
Article By: The Fly Sunday, December 23, 2018 10:40 PM EDT
Trump accuses Facebook, Twitter, and Google of being "biased;" White House blocks tax break for alcohol companies.
In this article: BF-A, FB, GOOGL, GOOG, TWTR, DEO, STZ, BF-B, AGN, AZN, NVS
Read
5 Drug/Biotech Stocks Likely To Beat Q3 Earnings Estimates
Article By: Zacks Investment Research Sunday, October 28, 2018 2:00 PM EDT
There are a number of drug/biotech companies poised to surpass third-quarter estimates. However, given the large number of drug/biotech firms, the task of selecting stocks with possibilities to beat could appear quite daunting.
In this article: REGN, AGN, AMGN, ALNY, AMAG
Read
Allergan Says Study Of Higher Doses Of BOTOX Meets Primary Endpoint
Article By: The Fly Friday, September 14, 2018 8:09 PM EDT
Allergan announced clinical study results of higher doses of BOTOX Cosmetic compared to BOTOX Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines.
In this article: AGN
Read
Allergan Upgraded To Buy From Neutral At Mizuho
Article By: The Fly Friday, August 3, 2018 9:31 AM EDT
Mizuho analyst Irina Koffler upgraded Allergan to Buy and raised her price target for the shares to $210 from $194.
In this article: AGN
Read
Pharma Stock Roundup: Mixed Q1 For MRK, PFE, FDA Nod For Kymriah's 2nd Indication
Article By: Zacks Investment Research Friday, May 4, 2018 8:15 PM EDT
First-quarter results of pharma bigwigs like Pfizer, Merck and Allergan stole the limelight this week. Other than that, Novartis gained FDA approval for the second indication of its CAR-T therapy, Kymriah.
In this article: AGN, JNJ, MRK, NVS, PFE, UTHR, ABBV
Read
Allergan Beats Q1 Earnings, Stock Up
Article By: Zacks Investment Research Monday, April 30, 2018 12:09 PM EDT
Allergan’s first-quarter earnings of $3.74 per share were above our consensus estimate of $3.36 per share.
In this article: AGN
Read
Should You Buy Allergan Plc When Prices Drop?
Article By: Matthew Hogan Wednesday, April 4, 2018 4:37 PM EDT
Allergan plc investors have enjoyed seeing the stock price increase by 16.9% over the last month.
In this article: AGN
Read
Allergan Slides After Mylan, Revance Report Deal For Botox Biosimilar
Article By: The Fly Thursday, March 1, 2018 12:25 PM EDT
Shares of Allergan are under pressure this morning after Mylan and Revance Therapeutics announced an agreement for the development and commercialization of a proposed biosimilar to Botox.
In this article: AGN Also: MYL, RVNC
Read
1 to 16 of 220 Posts
1 2 3 ... 14